JP2010515698A5 - - Google Patents

Download PDF

Info

Publication number
JP2010515698A5
JP2010515698A5 JP2009545143A JP2009545143A JP2010515698A5 JP 2010515698 A5 JP2010515698 A5 JP 2010515698A5 JP 2009545143 A JP2009545143 A JP 2009545143A JP 2009545143 A JP2009545143 A JP 2009545143A JP 2010515698 A5 JP2010515698 A5 JP 2010515698A5
Authority
JP
Japan
Prior art keywords
formula
compound
biphenyl
salt
nitrogen protecting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009545143A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010515698A (ja
JP5715339B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2008/000142 external-priority patent/WO2008083967A2/en
Publication of JP2010515698A publication Critical patent/JP2010515698A/ja
Publication of JP2010515698A5 publication Critical patent/JP2010515698A5/ja
Application granted granted Critical
Publication of JP5715339B2 publication Critical patent/JP5715339B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009545143A 2007-01-12 2008-01-10 5−ビフェニル−4−アミノ−2−メチルペンタン酸の製造方法 Active JP5715339B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07100451.9 2007-01-12
EP07100451 2007-01-12
PCT/EP2008/000142 WO2008083967A2 (en) 2007-01-12 2008-01-10 Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid

Publications (3)

Publication Number Publication Date
JP2010515698A JP2010515698A (ja) 2010-05-13
JP2010515698A5 true JP2010515698A5 (enExample) 2011-03-03
JP5715339B2 JP5715339B2 (ja) 2015-05-07

Family

ID=38124137

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009545143A Active JP5715339B2 (ja) 2007-01-12 2008-01-10 5−ビフェニル−4−アミノ−2−メチルペンタン酸の製造方法

Country Status (36)

Country Link
US (4) US8115016B2 (enExample)
EP (1) EP2121578B1 (enExample)
JP (1) JP5715339B2 (enExample)
KR (2) KR101580067B1 (enExample)
CN (1) CN101631765B (enExample)
AR (1) AR064842A1 (enExample)
AU (2) AU2008204546B2 (enExample)
BR (1) BRPI0806700A8 (enExample)
CA (1) CA2674291C (enExample)
CL (1) CL2008000077A1 (enExample)
CO (1) CO6251311A2 (enExample)
CY (1) CY1118225T1 (enExample)
DK (1) DK2121578T3 (enExample)
EC (1) ECSP099508A (enExample)
ES (1) ES2602566T3 (enExample)
GT (1) GT200900195A (enExample)
HR (1) HRP20161484T1 (enExample)
HU (1) HUE030695T2 (enExample)
IL (1) IL199492A (enExample)
JO (1) JO3142B1 (enExample)
LT (1) LT2121578T (enExample)
MA (1) MA31284B1 (enExample)
MX (1) MX2009007474A (enExample)
MY (2) MY153432A (enExample)
NZ (1) NZ577910A (enExample)
PE (2) PE20081563A1 (enExample)
PH (1) PH12012502091A1 (enExample)
PL (1) PL2121578T3 (enExample)
PT (1) PT2121578T (enExample)
RU (1) RU2530900C2 (enExample)
SG (1) SG185318A1 (enExample)
SI (1) SI2121578T1 (enExample)
TN (1) TN2009000296A1 (enExample)
TW (1) TWI413638B (enExample)
WO (1) WO2008083967A2 (enExample)
ZA (1) ZA200904311B (enExample)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12012502091A1 (en) * 2007-01-12 2019-06-14 Novartis Ag Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid
AU2012202949B2 (en) * 2008-01-17 2015-01-22 Novartis Ag Process and intermediates for the preparation of 5-biphenyl-4-yl-2-methylpentanoic acid derivatives
AR070176A1 (es) 2008-01-17 2010-03-17 Novartis Ag Procesos de sintesis de inhibidores de nep, compuestos intermediarios y uso de los mismos en la sintesis
JP5466759B2 (ja) 2009-05-28 2014-04-09 ノバルティス アーゲー ネプリライシン阻害剤としての置換アミノ酪酸誘導体
SG176009A1 (en) 2009-05-28 2011-12-29 Novartis Ag Substituted aminopropionic derivatives as neprilysin inhibitors
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
AU2011207020B2 (en) * 2010-01-22 2014-04-17 Novartis Ag Intermediates of neutral endopeptidase inhibitors and preparation method thereof
BR112013004164A2 (pt) 2010-08-23 2016-05-10 Novartis Ag processo para a preparação de intermediários para a produção de inibidores da nep
MX2013002149A (es) * 2010-08-23 2013-04-03 Novartis Ag Nuevo proceso para la preparacion de intermediarios utiles para la elaboracion de inhibidores de nep.
US8993631B2 (en) 2010-11-16 2015-03-31 Novartis Ag Method of treating contrast-induced nephropathy
US8877815B2 (en) * 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
CA2819153A1 (en) 2010-12-15 2012-06-21 Theravance, Inc. Neprilysin inhibitors
HUE028051T2 (hu) * 2010-12-15 2016-11-28 Theravance Biopharma R&D Ip Llc Neprilizin inhibitorok
JP5959066B2 (ja) 2011-02-17 2016-08-02 セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー ネプリライシン阻害剤としての置換アミノ酪酸誘導体
JP5959065B2 (ja) 2011-02-17 2016-08-02 セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー ネプリライシン阻害剤としての置換アミノ酪酸誘導体
CN103748070B (zh) 2011-05-31 2015-06-24 施万生物制药研发Ip有限责任公司 脑啡肽酶抑制剂
CN103582630B (zh) 2011-05-31 2016-08-17 施万生物制药研发Ip有限责任公司 脑啡肽酶抑制剂
JP5959074B2 (ja) 2011-05-31 2016-08-02 セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー ネプリライシン阻害剤
TWI560172B (en) 2011-11-02 2016-12-01 Theravance Biopharma R&D Ip Llc Neprilysin inhibitors
TWI562986B (en) * 2012-02-15 2016-12-21 Theravance Biopharma R&D Ip Llc Process for preparing 4-amino-5-biphenyl-4-yl-2-hydroxymethyl-2-methyl-pentanoic acid compounds
CA2871292A1 (en) 2012-05-31 2013-12-05 Theravance Biopharma R&D Ip, Llc Nitric oxide donor neprilysin inhibitors
SMT201700306T1 (it) 2012-06-08 2017-07-18 Theravance Biopharma R&D Ip Llc Inibitori di neprilisina
WO2013184898A1 (en) 2012-06-08 2013-12-12 Theravance, Inc. Neprilysin inhibitors
MX366149B (es) 2012-08-08 2019-06-28 Theravance Biopharma R&D Ip Llc Inhibidores de neprilisina.
JP6301371B2 (ja) 2013-02-14 2018-04-11 ノバルティス アーゲー インビボ効力が改善されたnep阻害剤としての置換ビスフェニルブタン酸誘導体
TR201808541T4 (tr) 2013-02-14 2018-07-23 Novartis Ag Nep (nötr endopeptidaz) inhibitörleri olarak ikame edilmiş bisfenil butanoik fosfonik asit türevleri.
DK2964616T3 (en) 2013-03-05 2017-08-28 Theravance Biopharma R&D Ip Llc Neprilysin inhibitors
CN104230865B (zh) * 2013-06-13 2018-01-09 上海翰森生物医药科技有限公司 联芳基取代的4‑氨基丁酸衍生物及其制备方法和用途
CA2934936A1 (en) 2014-01-30 2015-08-06 Theravance Biopharma R&D Ip, Llc Neprilysin inhibitors
CA2934898A1 (en) 2014-01-30 2015-08-06 Theravance Biopharma R&D Ip, Llc 5-biphenyl-4-heteroarylcarbonylamino-pentanoic acid derivatives as neprilysin inhibitors
LT3218351T (lt) 2014-11-14 2019-09-25 Zentiva K.S. Ahu-377 farmaciniu požiūriu priimtinų formų gavimo, atskyrimo ir gryninimo būdas
WO2016086798A1 (zh) * 2014-12-03 2016-06-09 上海翰森生物医药科技有限公司 Nep抑制剂结晶型游离酸、钙盐多晶型及其制备方法和应用
CN104557600B (zh) * 2015-01-26 2016-05-04 苏州明锐医药科技有限公司 沙库比曲的制备方法
JP6766055B2 (ja) 2015-02-11 2020-10-07 セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー ネプリライシン阻害剤としての(2s,4r)−5−(5’−クロロ−2’−フルオロビフェニル−4−イル)−4−(エトキシオキサリルアミノ)−2−ヒドロキシメチル−2−メチルペンタン酸
TW201632493A (zh) 2015-02-13 2016-09-16 諾華公司 新穎方法
LT3259255T (lt) 2015-02-19 2021-04-26 Theravance Biopharma R&D Ip, Llc (2r,4r)-5-(5`-chlor-2`-fluorbifenil-4-il)-2-hidroksi-4-[(5-metiloksazol-2-karbonil)amino]pentano rūgštis
WO2016135751A1 (en) 2015-02-25 2016-09-01 Mylan Laboratories Limited Novel process for the preparation of sacubitril and its intermediates
CN106187808A (zh) * 2015-05-08 2016-12-07 苏州鹏旭医药科技有限公司 Ahu-377的制备方法、ahu-377中间体及ahu-377中间体的制备方法
CN104829514B (zh) * 2015-05-12 2017-10-03 江苏福瑞生物医药有限公司 一种药物中间体的合成方法
CN104926707B (zh) * 2015-05-12 2017-10-27 江苏福瑞生物医药有限公司 一种药物中间体的合成方法
CN104860894B (zh) * 2015-06-10 2017-05-17 北京博全健医药科技有限公司 一种抗心衰药lcz696的制备方法
WO2016203500A2 (en) * 2015-06-19 2016-12-22 Actavis Group Ptc Ehf. Preparation of sacubitril or salt thereof and novel intermediates in the preparation of sacubitril
SI3317248T1 (sl) * 2015-07-02 2021-01-29 Novartis Ag Sakubitril kalcijeve soli
WO2017006254A1 (en) 2015-07-08 2017-01-12 Novartis Ag Drug combination comprising an angiotensin ii receptor antagonist, a neutral endopeptidase inhibitor and a mineralcorticoid receptor antagonist
CN105061263B (zh) * 2015-08-11 2017-03-15 苏州楚凯药业有限公司 一种nep抑制剂中间体的制备方法
CN105168205A (zh) * 2015-08-18 2015-12-23 泰力特医药(湖北)有限公司 一种血管紧张素ii受体和脑啡肽酶受体双重抑制剂lcz696的制备方法
WO2017033128A1 (en) 2015-08-25 2017-03-02 Novartis Ag Biphenyl-substitued 4-amino-butyric acid derivatives and their use in the synthesis of nep inhibitors
CN105130869B (zh) * 2015-09-07 2017-12-26 曾伟 一种Entresto中间体(S)‑5‑(联苯‑4‑羰基)吡咯烷‑2‑酮的合成方法
WO2017051326A1 (en) 2015-09-23 2017-03-30 Novartis Ag New processes and intermediates useful in synthesis of nep inhibitors
CN105348209B (zh) 2015-12-09 2017-12-26 浙江天宇药业股份有限公司 一种抗心衰药lcz696的制备方法
CN105523964B (zh) * 2015-12-09 2017-05-24 苏州楚凯药业有限公司 一种抗心衰药物中间体的制备方法
US10377697B2 (en) * 2015-12-10 2019-08-13 Novartis Ag Process and intermediates
EP3386945A1 (en) 2015-12-11 2018-10-17 Zentiva, K.S. Solid forms of (2r,4s)-5-(biphenyl-4-yl)-4-[(3-carboxypropionyl)amino]-2- -methylpentanoic acid ethyl ester, its salts and a preparation method
CN106977415B (zh) * 2016-01-15 2021-03-26 广东东阳光药业有限公司 一种沙库必曲的中间体及其制备方法
CN105566194A (zh) * 2016-02-01 2016-05-11 张伯引 一种Sacubitril中间体的制备方法
WO2017148357A1 (zh) 2016-02-29 2017-09-08 广东东阳光药业有限公司 一种沙库必曲的中间体及其制备方法
JP7306828B2 (ja) 2016-03-08 2023-07-11 セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー 結晶性(2s,4r)-5-(5’-クロロ-2’-フルオロ-[1,1’-ビフェニル]-4-イル)-2-(エトキシメチル)-4-(3-ヒドロキシイソオキサゾール-5-カルボキサミド)-2-メチルペンタン酸およびその使用
WO2017191620A1 (en) * 2016-05-06 2017-11-09 Sun Pharmaceutical Industries Limited A crystalline form of a salt of sacubitril and a process of its preparation
CN105924355B (zh) * 2016-05-11 2018-08-17 浙江宏元药业有限公司 沙库比曲中间体及沙库比曲中间体和沙库比曲的制备方法
US20190256454A1 (en) 2016-07-05 2019-08-22 Novartis Ag New process for early sacubitril intermediates
CN107602399B (zh) * 2016-07-11 2020-09-25 江西东邦药业有限公司 一种脑啡肽酶抑制剂中间体的制备方法
CN109563019A (zh) * 2016-08-17 2019-04-02 诺华股份有限公司 Nep抑制剂合成的新方法和中间体
CN106496055A (zh) * 2016-10-09 2017-03-15 杭州科巢生物科技有限公司 一种抗心衰新药的关键组分沙库比曲的新合成方法
WO2018069833A1 (en) * 2016-10-10 2018-04-19 Laurus Labs Limited Stable amorphous form of sacubitril valsartan trisodium complex and processes for preparation thereof
US10774036B2 (en) 2016-12-23 2020-09-15 Novartis Ag Process for early sacubitril intermediates
CN107311909A (zh) * 2017-06-22 2017-11-03 东南大学 一种lcz696杂质对照品的制备方法
CN109206419B (zh) * 2017-06-29 2023-07-14 上海迪赛诺化学制药有限公司 沙库比曲中间体及其制备方法和应用
PL3720838T3 (pl) * 2017-12-05 2022-12-19 Basf Se Sole organicznych kwasów sulfonowych i estrów aminokwasów i sposoby ich wytwarzania
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
CN110407733A (zh) * 2018-04-26 2019-11-05 鲁南制药集团股份有限公司 一种沙库巴曲杂质化合物
CN110551151A (zh) * 2018-05-30 2019-12-10 微宏动力系统(湖州)有限公司 一种磷酸酯或亚磷酸酯的制备方法、电解液及二次电池
CN108727213B (zh) * 2018-06-29 2021-06-08 中国科学院上海有机化学研究所 一种沙库必曲的制备方法
WO2020039394A1 (en) 2018-08-24 2020-02-27 Novartis Ag New drug combinations
CN109456212A (zh) * 2018-12-03 2019-03-12 康化(上海)新药研发有限公司 一种沙库比曲中间体的合成方法
CN109400504A (zh) * 2018-12-11 2019-03-01 重庆三圣实业股份有限公司 Lcz696中间体非对映异构体的分离纯化方法
EP3908572B1 (en) * 2019-01-08 2024-06-19 Basf Se Process for the preparation of organosulfate salts of amino acids esters
CN109912486B (zh) * 2019-04-25 2022-09-27 东北制药集团股份有限公司 一种联苯甲基内酰胺化合物的制备方法
CN110878039A (zh) * 2019-12-18 2020-03-13 株洲千金药业股份有限公司 一种沙库巴曲缬沙坦钠杂质的制备方法
JP7064527B2 (ja) * 2020-05-01 2022-05-10 ノバルティス アーゲー サクビトリルカルシウム塩
BR112023000293A2 (pt) 2020-07-09 2023-03-21 Advansix Resins & Chemicals Llc Tensoativos de aminoácidos ramificados
US12257333B2 (en) 2020-07-13 2025-03-25 Advansix Resins & Chemicals Llc Branched amino acid surfactants for personal care and cosmetic products
CN116075582B (zh) 2020-07-13 2025-08-19 艾德凡斯化学公司 用于清洁产品的支链氨基酸表面活性剂
WO2022015677A2 (en) 2020-07-13 2022-01-20 Advansix Resins & Chemicals Llc Branched amino acid surfactants for electronics products
US12071588B2 (en) 2020-07-13 2024-08-27 Advansix Resins & Chemicals Llc Branched amino acid surfactants for oil and gas production
CN116057130B (zh) 2020-07-13 2024-05-28 艾德凡斯化学公司 用于油墨、涂料和胶粘剂的支链氨基酸表面活性剂
EP4178537A1 (en) 2020-07-13 2023-05-17 AdvanSix Resins & Chemicals LLC Branched amino acid surfactants for use in healthcare products
CN115677521B (zh) * 2022-11-16 2024-02-02 迪嘉药业集团股份有限公司 一种高纯度沙库巴曲钙的制备方法
CN117447341B (zh) * 2023-09-06 2025-11-18 杭州国瑞生物科技有限公司 一种沙库巴曲缬沙坦钠中间体的精制方法
CN117756622B (zh) * 2023-12-21 2026-04-28 安徽皓元药业有限公司 一种沙库巴曲关键中间体的制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5015793B2 (enExample) 1972-06-07 1975-06-07
EP0055175B1 (fr) 1980-12-23 1984-06-13 Air Industrie Installations thermo-électriques
FR2597100A1 (fr) 1986-01-21 1987-10-16 Nippon Shinyaku Co Ltd Derives du pyroglutamide
PH24872A (en) 1986-08-25 1990-12-26 Schering Corp (5r,6s,8r)-6-(-1-hydroxyethyl)-2-(3r-pyrrolidin-2-one-3-yl)thiopenem-3-carboxylic acid
JPH07103101B2 (ja) * 1989-07-24 1995-11-08 キッセイ薬品工業株式会社 ピログルタミン酸誘導体
DE122007000050I1 (de) 1990-02-19 2007-11-08 Novartis Ag Acylverbindungen
US5273990A (en) 1992-09-03 1993-12-28 Ciba-Geigy Corporation Phosphono substituted tetrazole derivatives
US5250522A (en) * 1992-10-09 1993-10-05 Ciba-Geigy Corporation Phosphono/biaryl substituted amino acid derivatives
US5217996A (en) * 1992-01-22 1993-06-08 Ciba-Geigy Corporation Biaryl substituted 4-amino-butyric acid amides
DE69324106T2 (de) 1992-11-17 1999-12-09 Sankyo Co., Ltd. Krystallines Carbapenemderivat
ZA938438B (en) * 1992-11-17 1994-06-20 Sankyo Co Crystalline carbapenem derivative
US5550119A (en) 1995-03-02 1996-08-27 Ciba-Geigy Corporation Phosphono substituted tetrazole derivatives as ECE inhibitors
CN1216522A (zh) * 1996-02-19 1999-05-12 日本烟草产业株式会社 糖尿病治疗剂
WO2000017162A1 (en) * 1998-09-21 2000-03-30 Takeda Chemical Industries, Ltd. Novel thiol derivatives, process for producing the same and utilization thereof
NZ533968A (en) 2002-01-17 2006-10-27 Novartis Ag Pharmaceutical compositions comprising valsartan and nep inhibitors
ATE473216T1 (de) 2002-03-29 2010-07-15 Senju Pharma Co Hydroxymorpholinonderivat und dessen medizinische verwendung
US7618981B2 (en) 2004-05-06 2009-11-17 Cytokinetics, Inc. Imidazopyridinyl-benzamide anti-cancer agents
JP5017098B2 (ja) 2004-05-07 2012-09-05 ユミコア・アクチエンゲゼルシャフト・ウント・コムパニー・コマンディットゲゼルシャフト 均一系のエナンチオ選択的水素化触媒のためのフェロセニル配位子
GB0418046D0 (en) 2004-08-12 2004-09-15 Prosidion Ltd Eantioselective process
MY146830A (en) 2005-02-11 2012-09-28 Novartis Ag Combination of organic compounds
EP1903027A1 (en) 2006-09-13 2008-03-26 Novartis AG Process for preparing biaryl substituted 4-amino-butyric acid or derivatives thereof and their use in the production of NEP inhibitors
PH12012502091A1 (en) * 2007-01-12 2019-06-14 Novartis Ag Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid

Similar Documents

Publication Publication Date Title
JP2010515698A5 (enExample)
JP2007518723A5 (enExample)
JP2009120624A5 (enExample)
JP2013514257A5 (enExample)
JP2012517962A5 (enExample)
JP2008290071A5 (enExample)
JP2012111953A5 (enExample)
JP2013512223A5 (enExample)
JP2012516292A5 (enExample)
JP2014513036A5 (enExample)
JP2008235603A5 (enExample)
JP2010530897A5 (enExample)
ATE524476T1 (de) Pyrazolopyrimidine als modulatoren von caseinkinase ii (ck2)
EA200970149A1 (ru) Производные n-(аминогетероарил)-1h-индол-2-карбоксамидов, их получение и их применение в терапии
WO2008019372A3 (en) 2-aminobenzoxazole carboxamides as 5ht3 modulators
JP2010520214A5 (enExample)
JP2013500200A5 (enExample)
JP2014527200A5 (enExample)
JP2010529994A5 (enExample)
MX2007013203A (es) Nuevas aminas ciclicas.
JP2011242375A5 (enExample)
JP2010285401A5 (enExample)
WO2011126245A3 (en) Novel method of preparing vanadosilicate molecular sieve and novel vanadosilicate molecular sieve
JP2010508310A5 (enExample)
JP2013215640A5 (enExample)